Merck & Co Inc (XBUL:6MK)
лв 97.9 0 (0%) Market Cap: 475.39 Bil Enterprise Value: 520.01 Bil PE Ratio: 20.83 PB Ratio: 5.65 GF Score: 87/100

Merck & Co Inc at Evercore ISI HealthCONx Virtual Conference Transcript

Dec 01, 2021 / 03:30PM GMT
Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research

Excellent. Listen, let's try it again. I think we have Frank. We're going to jump right into it. Frank, let me turn it over to you for some opening comments, and we'll dig right in.

Franklin K. Clyburn
Merck & Co., Inc. - Executive VP & President Human Health

Sure, Umer. I'll be very brief. I just want to thank everyone for joining. We have a lot of excitement happening at Merck right now. We had a very strong quarter that we announced, both top and bottom line, good operational performance, Umer, good performance throughout the year. A lot of strategic actions that have taken place, the spin of Organon this year. We've announced the closing now of our Acceleron business development transaction.

And we're really excited to be a new, agile, focused management team. Obviously, we had an important AdCom yesterday, I'm sure we'll get into. And also this morning, we announced VAXNEUVANCE as an accelerated approval opportunity for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot